EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies



Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies



International Journal of Hematology 78(1): 32-39, July



Acute promyelocytic leukemia (APL) is now the most potentially curable subtype of acute myeloid leukemia in adults because of the introduction of novel approaches in the management of this disease. All-trans-retinoic acid (ATRA)-based therapy is now the first-choice treatment of patients presenting with de novo APL, and clinical studies have shown that nearly all patients who receive ATRA therapy achieve complete remission. However, approximately 20% to 30% of APL patients eventually have relapses with resistance to further ATRA treatment. Arsenic trioxide (As2O3 [ATO]) has been established as highly effective therapy for patients with APL, even for those with disease refractory to ATRA. Furthermore, results of recent studies have suggested a broad therapeutic potential for ATO in the treatment of hematologic malignancies beyond APL. In this review, we discuss the clinical activity and multiple mechanisms of ATO therapy in the management of APL and other hematologic neoplasms.

(PDF emailed within 0-6 h: $19.90)

Accession: 011591107

Download citation: RISBibTeXText

PMID: 12894848

DOI: 10.1007/bf02983237



Related references

Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leukemia & Lymphoma 42(6): 1265-1273, 2002

Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Blood Reviews 15(3): 133-142, 2001

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 7 Suppl 1: 1-13, 2002

Arsenic trioxide in the treatment of acute promyelocytic leukemia Basic mechanisms and clinical results. Annals of Hematology 77(SUPPL 2): S19, 1998

Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide. Journal of Clinical Oncology 19(19): 3993-3995, 2001

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10): 3315-3324, 1999

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage. Leukemia (Basingstoke) 15(5): 735-741, 2001

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5): 735-741, 2001

On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia. Leukemia Research Reports 7: 29-32, 2017

Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 90(9): 1231-1235, 2005

Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. Haematologica 87(5): 452-453, 2002

Clinical observation on arsenic trioxide in the treatment of acute promyelocytic leukemia. Experimental Hematology (Charlottesville) 25(8): 866, 1997

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biology of Blood and Marrow Transplantation 15(11): 1479-1484, 2009

Clinical observation on arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 92(10 SUPPL 1 PART 1-2): 404A, Nov 15, 1998

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer ChemoTherapy and Pharmacology 40 Suppl: S36-S41, 1997